Just to add
'stats dudes at FDA strongly suggested Overall PFS as the primary.'
The rationale was that OPFS is accepted as a proxy for OS, which is of course the long game. The trial results may confirm this, or blow it away. 8 weeks to find out
Roll on the HCC data - unfortunately some time to wait, and in the meantime it is down to business as usual and increasing sales each year, hopefully.
SRX Price at posting:
$20.80 Sentiment: Hold Disclosure: Held
